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Abstract—Mechanical factors play a key role in activation of cardiac growth factor response in hemodynamic overload,
and both cooperate in myocardial remodeling. The present study was performed to investigate whether a different
growth factor response is activated in the right and left ventricles in aortocaval fistula and its effects on regional
myocardial adaptation. Relations between regional growth factor expression (angiotensin II, insulin-like growth factor-I,
and endothelin-1), myocyte shape changes, and collagen deposition were investigated at mRNA and peptide levels in
adult pigs after the creation of an aortocaval fistula distal to the renal arteries (n15) and in sham-operated animals
(n15). The role of angiotensin II was investigated by the administration of angiotensin-converting enzyme inhibitor
or angiotensin II receptor antagonist. In the left ventricle, pure volume overload was accompanied by persistent increase
of insulin-like growth factor-I mRNA expression, peptide concentration (2.2-fold versus sham at 3 months, P0.05),
and significant increase of myocyte length (29% at 3 months, P0.05). Conversely, the mixed pressure-volume
overload faced by the right ventricle resulted in significant regional overexpression of all growth factors investigated
(angiotensin II, insulin-like growth factor-I, and endothelin-1), with corresponding increase of myocyte diameter and
length and collagen deposition (117% at 3 months). Collagen accumulation in the right ventricle as well as the increase
in right ventricular end-diastolic pressure at the 3-month observation were inhibited by angiotensin II antagonism. The
left and right ventricles respond differently to aortocaval fistula, and local growth factor expression is closely related
to the regional myocardial adaptation. (Hypertension. 2004;43:1-8.)
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Human and experimental studies indicate that a differen-tial pattern of growth factor gene activation is evoked by
pressure and volume overload, respectively, with overexpres-
sion of angiotensinogen (AGTN), prepro-endothelin-1
(ppET-1), and insulin-like growth factor-I (IGF-I) or isolated
activation of IGF-I production.1–3 In the acute phase, growth
factor gene expression contributes to maintain left ventricular
cardiac function,4 whereas in the long term it regulates the
pattern of hypertrophy by affecting myocyte growth5,6 and
collagen deposition.7 Increased collagen accumulation char-
acterizes concentric hypertrophy of experimental pressure
overload,8 whereas no significant changes in fibrillar collagen
content have been observed in experimental volume-induced
eccentric hypertrophy.9,10 The pattern of growth factor gene
expression is then finally modified by the transition from
hypertrophy to failure with enhanced angiotensin II (Ang II)
formation and reduced IGF-I expression.11 Thus, the expres-
sion of local growth factors appears to participate in the
regulation of the type of cardiac hypertrophy and to charac-
terize the transition to failure.
In aortocaval fistula, the two ventricles are both exposed to
increased work load, but experimental studies performed in
rats indicate that in addition to volume overload, the right
ventricle also faces an increased pressure load caused by the
rise in pulmonary systolic pressure,12–14 leading to a relative
mass increase higher in the right than in the left ventricle.2,13
The increased magnitude of right ventricular hypertrophy has
also been associated with enhanced collagen accumulation.15
However, in the large majority of studies on experimental
aortocaval fistula, growth factor changes and ventricular
function have been investigated only in the left ventricle,16–18
with no direct comparison of growth factor response in the
two different cardiac chambers. Only a single study compared
the local expression of IGF-I in the right and left ventricles of
rats with aortocaval fistula,2 even though IGF-I is not directly
involved in myocardial fibrosis. On the other hand, the
activation of the renin-angiotensin system (RAS), which
conversely is known to directly stimulate both collagen
deposition7 and overexpression of other fibrogenic growth
factors,4 has only been investigated through administration of
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angiotensin-converting enzyme (ACE) inhibitors and angio-
tensin type 1 (AT1) receptor antagonists, which modified the
cardiac load.2,15,19 All these experimental studies were per-
formed in rats, which respond to acute volume overload
differently from large animals. The high cardiac output in
volume-overloaded rats was indeed accomplished solely by
increased stroke volume, with no changes in heart rate.12 In
addition, the majority of studies have only investigated the
mechanics of the left ventricle,16,17 revealing normal indexes
of left ventricular function with shortening velocity decreas-
ing only at the terminal stage of heart failure.20 However, the
presence of increased hepatic fluid content and ascites at
chronic assessment may suggest an approaching right ven-
tricular failure.13
Therefore, the present study was designed to compare the
hemodynamic adaptations, growth factor (Ang II, ET-1, and
IGF-I) expression, and collagen deposition in the right and
left ventricles during the development (up to 3 months) of
volume overload–induced (aortocaval fistula) myocardial hy-
pertrophy in pigs. In addition, an ACE inhibitor (ramipril) or
AT1 receptor antagonist (valsartan) was administered in two
groups of animals to investigate the relative role of Ang II on
myocardial hypertrophy and collagen deposition in the two
ventricles.
Methods
Animals and Study Design
Thirty-six farm pigs of either gender, weighing 382 kg, were used
in the study. Animals were kept and handled in accordance with the
recommendations of the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85 to 23, Revised 1996). Animals were anesthetized,
and volume overload was induced in 15 animals by creating an
infrarenal aortocaval fistula (Dacron graft, 8 mm diameter), as
previously described,3 whereas 15 animals were sham-operated. At
baseline and at 15, 30, 60, and 90 days after surgery, 3 aortocaval-
shunted animals and 3 sham-operated animals underwent echocar-
diographic examination and measurements of hemodynamic param-
eters. After the pigs were euthanized, the heart was removed, and 2
transmural left and right ventricular free wall specimens, taken
midway from base to apex, were immediately placed in liquid
nitrogen for measurement of ET-1, IGF-I, Ang II, and hydroxypro-
line cardiac content and for RT-PCR studies and in 10% formalin
solution for myocyte morphometry.
Three days after surgery, 6 operated animals were randomized to
treatments with ACE inhibitor (ramipril, 5 mg per day; n3) or AT1
receptor antagonist (valsartan, 80 mg daily orally; n3), and
treatments were continued for 3 months. The doses of valsartan and
ramipril were preliminarily checked to reduce (60% to 40% inhibi-
tion at 3 and 24 hours, respectively) the increase in mean arterial
pressure after Ang II or Ang I infusion, respectively, without causing
any significant effect on resting blood pressure.4
Ventricular Function and
Hemodynamic Measurements
Two 6F pigtail catheters were introduced into the left femoral artery
and advanced to monitor left ventricular pressure. A pulmonary
artery catheter was used to measure capillary wedge pressure
(PCWP), pulmonary artery pressure (PAP), right atrial pressure
(RAP), cardiac output (CO), and cardiac index (CI). Echocardio-
graphic measurements were taken according to the recommendations
of the American Society of Echocardiography21; left ventricular
mass indexed by body weight (LVMI), left ventricular volumes (v),
and left ventricular meridional wall stresses were calculated by
means of standard formulas, as previously reported.4 Left ventricular
stroke work index was calculated as LVSWI(mean
AoPPCWP)SVI, where AoP is aortic pressure and SVI is stroke
volume index, which equals CI divided by heart rate.
Right ventricular stroke work index (RVSWI) was calculated as22
RVSWI(mean PAPmean RAP)SVI.
Measurements were analyzed independently by two experienced
echocardiographers. Interobserver and intra-observer variabilities
were 4.10.5% and 2.50.3% for cavity size and 3.70.4% and
2.10.3% for wall thickness, respectively.
Quantification of Growth Factor mRNA and
Peptide Levels in Myocardium
Myocardial levels of ppET-1, AGTN, and IGF-I transcripts were
quantified by RT-PCR with glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as internal standard, using specific primers (Table 1),
as previously reported.1
Measurements of Ang II concentration in myocardial tissue were
performed by RIA assay after preliminary acid-alcohol extraction
and concentration on Sep-Pak cartridges for HPLC separation as
previously described.4 Cardiac ET-1 was determined by specific RIA
assay according to Wei et al.23 IGF-I was assayed with RIA in
homogenated tissue according to Jalil et al.24
Myocardial Collagen Content and
Myocyte Morphometry
Myocardial collagen concentrations were measured by the hy-
droxyproline assay according to Woessner.25 To measure myocyte
and sarcomere lengths, the myocytes were isolated from formalin-
fixed tissue by means of the potassium hydroxide digestion method,
according to Tamura et al.26 Briefly, small pieces of formalin-fixed
tissue were rinsed in PBS and put into 12.5 mol/L KOH solution for
24 hours. Rod cells were then separated by filtration through nylon
mesh (250 m).
Statistical Analysis
Data are expressed as meanSD. Comparisons were performed by
means of 1-way ANOVA and the Student t test, followed by the
Tukey multiple-range comparison test, as appropriate. Linear rela-
tions were analyzed with the Pearson correlation, with the use of
BMDP statistical software (BMDP Statistical Software Inc).
An expanded Methods section can be found in an online supple-
ment available at http://www.hypertensionaha.org.
Results
Hemodynamic Changes
The fistula remained pervious in all experimental animals,
and no animal showed signs of heart failure or ascites during
the study. In operated animals, LVMI was 2.1-fold versus
TABLE 1. GAPDH, AGTN, ppET-1, and IGF-I Primers for RT-PCR
Primers Sequence 5—3 cDNA Sizes, bp
GAPDH 5TGAAGGTCGGAGTCAACGGA 987
3CATGTGGGCCATGAGGTCCA
AGTN 5CTGCAAGGATCTTATGACCT 238
3TACACAGCAAACAGGAATGG
ppET-1 5GTCAACACTCCCGAGCACGTT 304
3CTGGTTTGTCTTAGGTGTTCCTC
IGF-I 5ACATCTCCCATCTCTCTGGATTTCCTTTTGC 510
3CCCTCTACTTGCGTTCTTCAAATGTACTTCC
GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase; AGTN, angio-
tensinogen; ppET-1, prepro-endothelin-1; and IGF-I, insulin-like growth
factor-I.
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sham at 3 months (from 2.10.5 g/kg to 4.30.5 g/kg,
P0.001).
As a consequence of the creation of an aortocaval fistula,
total peripheral resistance significantly decreased and CO
significantly increased, remaining high versus sham at all
experimental times (Figure 1A and Table 2). Heart rate
increased after surgery but returned to baseline levels at 2
months (Figure 1B). The high CO then was accomplished
solely by the increase in stroke volume (Figure 1C).
Right ventricular pressure significantly increased after
surgery, whereas left ventricular pressure remained un-
changed (Figure 2). As a consequence, the RVSWI showed a
larger increase than the LVSWI (216% and 70% versus
baseline at 2 weeks, respectively) (Figure 2). At all the
following observation times, the LVSWI remained almost
steady (Figure 2). The left ventricular end-systolic stress
(ESS) was nonsignificantly different versus sham at all
experimental times, and the preload-independent index ESS/
end-systolic volume index (ESVI) ratio remained signifi-
cantly reduced versus sham at all the experimental times
(Table 2), thus indicating a persistent normal left ventricular
contractile function. Conversely, the end-diastolic right ven-
tricular pressure significantly increased at the 3-month obser-
vation versus values measured at 2 months, concomitant with
a significant reduction of the RVSWI (Figure 2).
The development of left ventricular hypertrophy as well as
the hemodynamic changes induced by aortocaval fistula were
not affected by the Ang II antagonism (Figure 1). However,
Figure 1. Cardiac output (A), heart rate (B), and stroke volume (C) in
pigs with aortocaval fistula treated with placebo (; n15), ramipril (;
n3), or valsartan (‘; n3) and in sham-operated animals (; n15).
Each point at different experimental times represents meanSD of 3
pigs. Values obtained at each experimental time in shunted animals
are compared with both baseline values measured in the same pig
and values measured at the same experimental time in 3 sham-
operated pigs. *P0.05 vs baseline and vs sham.
TABLE 2. Hemodynamic Changes Following the Creation of Aortocaval Fistula
Baseline 2 Weeks 1 Month 2 Months 3 Months
Shunt
LVESD, mm 231 262* 292* 312* 341*
LVEDD, mm 352 421* 451* 511* 552*
SWT, mm 11.81.2 12.30.4* 13.10.2* 12.90.5* 14.00.8*
DWT, mm 7.30.5 6.80.7 9.00.6* 9.70.5* 10.00.8*
LVMI, g/kg 2.110.45 3.200.10* 3.420.30* 3.820.21* 4.320.53*
PVR, mm Hg · mL1 · min · kg 1.960.50 0.750.04* 0.740.10* 0.730.11* 0.810.13*
LVEDP, mm Hg 7.72.6 9.81.3 10.00.6 9.01.3 11.04.9
RVEDP, mm Hg 6.82.8 10.00.9* 10.81.0* 11.50.5* 19.62.6*†
ESS, kdyne/cm2 478 525 564 605 663
ESS/ESVI 16327 1347* 13118* 1539* 1377*
EF, % 606 684 685 723 675
Sham
LVESD, mm 232 232 241 261 271
LVEDD, mm 342 351 372 392 421
SWT, mm 10.70.6 10.80.8 11.30.8 11.50.5 11.70.6
DWT, mm 7.30.6 7.20.3 7.20.3 7.70.3 8.20.3
LVMI, g/kg 2.060.22 1.980.12 2.070.28 1.860.26 1.980.19
PVR, mm Hg · mL1 · min · kg 1.770.31 1.610.31 1.210.29 1.330.14 1.380.05
LVEDP, mm Hg 7.34.2 7.03.6 7.72.9 7.02.6 6.32.5
RVEDP, mm Hg 4.31.5 5.01.7 4.00.1 5.00.1 5.30.6
ESS, kdyne/cm2 538 549 547 565 586
ESS/ESVI 17929 18020 15611 18913 19321
EF, % 622 644 675 683 673
Values are meanSD. DWT indicates diastolic wall thickness; EF, ejection fraction; ESS, end-systolic stress; ESVI,
end-systolic volume index; LVEDD left ventricular end-diastolic diameter; LVEDP left ventricular end-diastolic
pressure; LVESD, left ventricular end-systolic diameter; LVMI, left ventricular mass index; PVR, peripheral vascular
resistance; RVEDP right ventricular end-diastolic pressure; and SWT, systolic wall thickness.
*P0.05 vs sham; †P0.05 vs 2 months.
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both ACE inhibitor (ramipril) and AT1 antagonist (valsartan)
blunted the final increase (3-month) of the end-diastolic right
ventricular pressure detectable in untreated animals with
aortocaval fistula (11.21.9 and 10.51.3 mm Hg in ACE-
and AT1-blocked animals, P0.05 versus untreated animals).
Myocardial Collagen and Morphometry
Three months after application of the aortocaval fistula, the
collagen concentration in the right ventricle was 2-fold versus
sham (117%), with only a minor increase (29%) in the
left ventricle (Figure 3). The long-term administration of AT1
antagonist to animals with an aortocaval fistula significantly
reduced collagen deposition in the right ventricle (37%
versus placebo, P0.01), whereas no changes were observed
in the left ventricle (Figure 3). Conversely, ACE inhibition
reduced collagen concentration in the myocardial tissue of
both the right and the left ventricles (58% and 35%,
respectively, P0.05 for both versus placebo).
The length of cardiomyocytes was significantly increased
versus sham at 1 month in both ventricles (Figure 4).
Myocytes isolated from the left ventricle showed progressive
elongation up to the last experimental time, whereas the
length increase in right ventricular myocytes did not progress
further from the second to the third month (Figure 4). In
addition, different from left ventricular myocytes, right ven-
tricular myocytes showed a significant increase in cell trans-
verse size at 2 and 3 months versus sham (Figure 4). The
creation of an aortocaval fistula did not modify sarcomere
length either in the left ventricle (1.970.09 and 1.960.08
m in sham and shunted pigs at 3 months, respectively) or in
the right ventricle (2.080.05 and 2.060.08 m). The rate
of cardiomyocyte growth was unaffected by ACE inhibitor
and AT1 antagonist administration.
Growth Factor Production
In overloaded right ventricles of animals with aortocaval
fistula, both the AGTN and ppET-1 genes were markedly
activated (Figure 5). The AGTN/GAPDH mRNA ratio was
3.5-fold versus sham at 2 weeks, and the ppET-1 gene was
9.3-fold versus sham after 1 month. Both transcripts remained
overexpressed at the following observation periods (4.1-fold
and 7.8-fold versus sham at 3 months, respectively). Con-
versely, both the AGTN and the ppET-1 genes in the left
ventricle were unaffected by volume overload (Figure 5). The
selective increase of both Ang II and ET-1 formation in the
right ventricle of animals with aortocaval fistula was con-
firmed by radioimmunological assays at the peptide level
(Figure 6). At univariate analysis, myocardial ET-1 concen-
tration was positively related to myocyte diameter (r0.49,
P0.01)
The IGF-I mRNA expression in the myocardial tissue was
conversely enhanced both in the right and in left ventricles at
1 month and remained overexpressed at 2 months (Figure 5
and Figure 6). Then, at 3 months, IGF-I mRNA expression
and peptide concentration further increased in the left ventri-
cle versus values measured at 2 months, whereas in the right
ventricle IGF-I mRNA expression and peptide concentration
showed a sharp reduction (Figure 5 and Figure 6). Univariate
analysis revealed that regional IGF-I myocardial concentra-
tion was related to both SWI (r0.74 and r0.55 in the right
Figure 2. Left (A) and right (B) ventricular systolic (circles) and
diastolic (squares) pressure in volume-overloaded (filled sym-
bols) and sham-operated animals (empty symbols). C, Changes
in right ventricular () and left ventricular () stroke work index
induced by aortocaval fistula versus sham. Each point at differ-
ent experimental times represents meanSD of 3 pigs. Values
obtained at each experimental time in shunted animals are com-
pared with both baseline values measured in the same pig and
values measured at the same experimental time in 3 sham-
operated pigs. *P0.05 vs baseline; †P0.05 vs sham;
‡P0.05 vs values measured at 2 months.
Figure 3. Collagen concentration at 3 months after surgery in
right (filled bars) and left (open bars) ventricular myocardium of
sham-operated animals and of shunted pigs treated with pla-
cebo, valsartan, or ramipril. Each bar represents meanSD of 3
pigs. *P0.05 vs sham; †P0.05 vs placebo.
Figure 4. Length (A) and diameter (B) of myocytes isolated from
the left ventricle () and right ventricle () of shunted pigs. Each
point at different experimental times represents meanSD of 3
pigs. Values obtained at each experimental time are compared
with values obtained in sham-operated animals. *P0.05 vs
sham.
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and the left ventricle, respectively, P0.05 for both) and
myocyte length (r0.50, P0.05).
AT1 antagonism significantly reduced the myocardial con-
centration of Ang II in the right ventricle (389 pg/g versus
6410 pg/g in treated and untreated animals, respectively,
P0.05) and a complete normalization was induced by ACE
inhibition (258 pg/g, NS versus sham) (Figure 6). Both
valsartan and ramipril significantly reduced the ET-1 concen-
tration in the right ventricle (Figure 6). Conversely, IGF-I
myocardial concentration in the right ventricle was increased
by both ACE inhibition and AT1 antagonism (Figure 6).
Discussion
The main findings of the present study are that in chronic
aortocaval shunt (1) the different experimental mechanical
load and geometry of the two ventricles induce a distinct
regional pattern of activation of cardiac growth factors, with
overexpression of AGTN and ppET-1 genes restricted to the
right ventricular myocardium (facing both pressure and vol-
ume overload) and IGF-I gene expression activated in both
ventricles; (2) the different patterns of growth factor expres-
sion selectively regulate the adaptation of myocyte shape to
mechanical load (IGF-I for cell length and ppET-1 for cell
Figure 5. Expression of GAPDH, AGTN,
ppET-1, and IGF-I mRNAs in the right
ventricle (left panel) and left ventricle
(right panel) of volume-overloaded pigs.
Top panels: Representative RT-PCR
experiment. Bottom panels: Percent
increase in densitometric ratio to GAPDH
for AGTN (), ppET-1 (), and IGF-I (▫) in
shunted animals. Each point at different
experimental times represents meanSD
of values measured in 3 volume-
overloaded pigs. *P0.05 vs sham.
Figure 6. Left panels: Concentrations of
Ang II, ET-1, and IGF-I in myocardial tis-
sue of the right ventricle () and left ven-
tricle () of pigs with aortocaval fistula.
Right panels: Effect of AT1 antagonism
and ACE inhibition on myocardial con-
centration of Ang II, ET-1, and IGF-I in
the right ventricle (filled bars) and left
ventricle (empty bars) of pigs with aorto-
caval fistula. Each point at different
experimental times represents meanSD
of 3 pigs. *P0.05 vs sham; †P0.05 vs
placebo; ‡P0.05 vs 2 months.
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diameter increase) and affect collagen deposition (AGTN and
ppET-1); (3) a reduction of IGF-I production in the right
ventricle at 3 months occurred simultaneously with increased
right ventricular end-diastolic pressure.
Hemodynamic and Cardiac Adaptations to
Aortocaval Fistula
In our animals, the creation of an aortocaval shunt caused a
persistent 2.4-fold increase in CO versus sham-operated
animals, resulting in a 2.1-fold increase of LVMI at 3 months,
in agreement with previous studies.2,13,27,28 Unlike in rats,12
our pigs had CO that was mainly sustained by heart rate
during the first month. Only at 2 and 3 months after surgery
did dilation of the cardiac chamber cause CO to be chroni-
cally maintained by increased stroke volume, because heart
rate returned to baseline. Investigation of cell morphometry
offers further insight into the mechanism of cardiac adapta-
tion in large mammals. We used the potassium hydroxide
digestion method to obtain high-quality data on cell and
sarcomere length not otherwise possible with standard tissue
sectioning methods. The constant midwall sarcomere length,
also observed in dogs with severe volume overload induced
by arteriovenous shunt,29 clearly indicates that the chronic
cardiac adaptation to severe volume overloading does not
utilize the Frank-Starling mechanism. The pattern of adapta-
tion is rather related to the progressive addition of new
sarcomeres (11 and 8 per month in the right ventricle and left
ventricle, respectively). Indeed the final increase in myocyte
length, which became significant at 1 month after surgery,
accounts for most of the 45% to 50% increase in the left
ventricular chamber circumference at 3 months.
Although in isolated myocytes the cell diameter data
probably represent major diameters and may not truly repre-
sent overall changes in transverse myocyte size, cell mor-
phometry showed a different myocyte adaptation to aortoca-
val fistula in the two ventricles because notwithstanding the
length of both right and left ventricular myocytes was
increased, only right ventricular myocytes showed a progres-
sive increase in cell diameter at subsequent observations.
However, the 63% increase in right ventricular systolic
pressure indicates that in agreement with previous stud-
ies,12,28 the right ventricle in aortocaval fistula faces a mixed
pressure-volume overload, whereas the left ventricle faces a
pure volume overload with a selective increase in diastolic
stress.2,12,14,30 As a consequence, the acute stroke work
increase was 3.1-fold higher in the right than in the left
ventricle after the creation of an aortocaval fistula.
In our experimental model, the left ventricular hypertrophy
at 3 months was compensatory, as the ESS/ESVI ratio, an
index used to investigate left ventricular contractile function
in volume overload,31 did not increase. The complex geom-
etry of the right chamber makes difficult the calculation of
right ventricular wall stresses.32 However, the right ventric-
ular performance, expressed by RVSWI, was reduced at 3
months versus values measured at 2 months. The approach of
a right ventricular dysfunction at 3 months was also indicated
by the contemporary 70% increase in end-diastolic pressure
versus values measured at 2 months.
The factors responsible for the adaptation of myocyte
shape and ventricular function to the different mechanical
load are poorly understood, but the present study offers
relevant insights into the possible role of regional growth
factor expression.
Differential Activation of Growth Factors in the
Right and Left Ventricles
One of the main findings of the present study is that the
different mechanical loads faced by the two ventricles in
aortocaval fistula induce distinct regional growth factor gene
activation, with overexpression of AGTN, ppET-1, and IGF-I
in the right ventricle and isolated overexpression of IGF-I in
the left ventricle. Growth factor overexpression in the right
ventricle exposed to a mixed pressure-volume overload per-
sists during the chronic phase. Previous studies showed that
in pressure-overloaded left ventricles, the overexpression of
AGTN and ppET-1 soon recedes (within 24 hours) when the
ESS is normalized.3 The different mechanical properties of
the right and the left ventricular walls might be responsible
for the persistent enhancement of AGTN and ppET-1 gene
expression observed in the present study. Indeed, notwith-
standing the fact that the pressure increase faced by the right
ventricle of volume-overloaded pigs (26 mm Hg) was
lower than the pressure increase applied to the left ventricle of
aortic-banded pigs in the previous study (60 mm Hg), the
percent pressure increases versus baseline levels were similar
(63% and 50% respectively). Therefore, because of its
thin wall, the right ventricle might be unable to normalize
wall stress.
In our animals, a close relation was observed between the
cardiac expression of IGF-I and mechanical load, as also
revealed in patients with aortic valve disease,1 and healthy
athletes.33 Also for IGF-I, the regional cardiac formation
appears to be elicited by the stretching of the single myocyte
rather than by the absolute mechanical load applied to the
ventricle, as also reported in skeletal muscle fibers.34 Indeed,
during the early period after the application of aortocaval
fistula, cardiac IGF-I production was prevalent in the right
ventricle, even though it faces an absolute work load lower
than that of the left myocardium. The mechanical character-
istics of the ventricular wall may therefore determine the
profile of growth factor gene expression.
Activated Growth Factors and Ventricular
Adaptation to Increased Work Load
The IGF-I, overexpressed in both the right and left ventricles,
appears to play a key role in sustaining myocyte adaptation to
volume overload. In isolated myocytes, IGF-I has been
reported to induce the “in series” apposition of new sarco-
meres.35 In the present study, IGF-I was positively related to
myocyte elongation, a change that determines the final
adaptation of ventricles to volume overload. On the other
hand, ET-1 was positively related to myocyte transverse size.
ET-1 has indeed been reported to induce myocyte growth
with “in parallel” apposition of new contractile elements.36
Administration of Ang II antagonists indicates that Ang II
plays a minor role in myocardial hypertrophy induced by
aortocaval fistula. Neither AT1 receptor nor ACE inhibition
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affected the development of left ventricular hypertrophy. This
appears to be in contrast to previous findings in small
animals.19,37 However, different from the quoted studies, we
used drug doses that counteract Ang I–induced or Ang
II–induced pressure increases but did not affect baseline
blood pressure. Therefore, the dose used was adequate to
block the AT1 receptor and cardiac ACE but did not affect
mechanical load. In addition, in agreement with previous
studies,38 a reduction of myocardial Ang II was indeed found
in animals assigned to ACE inhibition. Therefore, the present
experiments argue against a direct involvement of RAS in the
development of cardiac hypertrophy in aortocaval fistula.
According to the present data, Ang II appears to play a
primary role in collagen deposition. A selective increase in
collagen concentration in the right myocardium was previ-
ously observed in small animals with aortocaval fistula9,10,15
and in human congenital heart disease with mixed pressure
and volume right ventricular overload.39 However, because of
the treatment protocol and the difficulty to perform accurate
dose findings in small animals, previous studies failed to
observe changes in cardiac collagen in animals treated with
Ang II antagonists. In our animals, AT1 blockade reduced
collagen deposition in the right ventricle. AT1 receptors,
which are the prevalent receptor subtype in isolated fibro-
blasts, are known to stimulate collagen synthesis.40,41 The
present data do not allow us to exclude that Ang II binding to
unblocked AT2 receptors might participate in the inhibition
of collagen synthesis, as previously hypothesized.42 On the
other hand, an even larger inhibition of collagen deposition
was found in the animals treated with the ACE inhibitors
when compared with the group allocated to the AT1 antag-
onist. Although a definitive clarification of the importance of
bradykinin would require further study with direct measure-
ment of the bradykinin levels, the beneficial effect of the
ACE inhibitor-mediated potentiation of the kinin system may
be at least hypothesized.43,44
Ang II inhibition also limited the reduction of IGF-I in the
right ventricle, and this effect might be related to the reduced
collagen deposition. IGF-I synthesis can be activated by
either sympathetic activity through extracellular signal regu-
lated kinase–mediated activation of GATA445 and through
mechanical stretching.46,47 The prevalent IGF-I expression in
the right ventricular myocardium in the presence of a com-
mon exposition to sympathetic system overactivity suggests a
prevalent role for the mechanical stimulus. Enhanced colla-
gen accumulation in the right ventricle might thus limit
myocyte stretching by reducing the sensitivity of myocyte
mechanosensors and contributing to the decline of the right
ventricular IGF-I formation observed at 3 months. Collagen
deposition might thus affect cardiac function, not only by
impairing cardiac compliance but also by limiting the en-
hancement of IGF-I formation. A reduction of IGF-I cardiac
production concurrently with the impairment of left ventric-
ular function has previously been observed in patients with
aortic valve disease1 and in experimental animals.48 Accord-
ing to the present findings, IGF-I expression might also play
a role in supporting right ventricular function, as indicated by
the close relation between regional IGF-I peptide level and
right ventricular performance expressed by RVSWI. The
clinical mark of reduced IGF-I production was the increase in
end-diastolic pressure. Indeed, the reduced IGF-I overexpres-
sion in the right ventricle at 3 months versus values measured
at 2 months occurred simultaneously with the reduction of
RVSWI and with the contemporary increase in end-diastolic
pressure. The measurement of peptide concentration in myo-
cardial tissue confirmed that both gene transcription and
peptide myocardial concentration reduce with increased dia-
stolic pressure. The relation among collagen deposition,
impaired IGF-I cardiac production, and reduced function is
further stressed by the effect of Ang II inhibition.
In conclusion, the present study indicates that the interac-
tion between the characteristics of the ventricular wall and the
mechanical load is a determinant for local cardiac growth
factor expression, which regulates the adaptation of myocyte
shape and interstitial matrix deposition to mechanical load.
On the basis of the present findings, it may be hypothesized
that Ang II–induced and ET-1–induced collagen accumula-
tion in the right ventricle might limit myocyte ability to sense
the mechanical load, leading to reduced IGF-I expression and
impaired ventricular performance.
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